Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study

OBJECTIVE: To evaluate the efficacy and safety of olokizumab (OKZ) in patients with active rheumatoid arthritis despite treatment with methotrexate (MTX). METHODS: In this 24-week multicentre, placebo-controlled, double-blind study, patients were randomised 1:1:1 to receive subcutaneously administer...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasonov, Evgeniy, Fatenejad, Saeed, Feist, Eugen, Ivanova, Mariana, Korneva, Elena, Krechikova, Diana G, Maslyanskiy, Aleksey L, Samsonov, Mikhail, Stoilov, Rumen, Zonova, Elena V, Genovese, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921576/
https://www.ncbi.nlm.nih.gov/pubmed/34344706
http://dx.doi.org/10.1136/annrheumdis-2021-219876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921576/
https://www.ncbi.nlm.nih.gov/pubmed/34344706
http://dx.doi.org/10.1136/annrheumdis-2021-219876

Ejemplares similares